Neurological disorders affect hundreds of millions of people worldwide, and for many patients, existing treatments fall short. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is working to change that with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.
Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS worldwide, with about one million in the United States. The disease is most often diagnosed between ages 20 and 50, affects females at roughly twice the rate of males, and has a mean age of 32 globally. Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
In addition to MS, the company has developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product addresses the widespread issue of alcohol-related cognitive impairment, which affects millions who consume alcohol.
The company’s dual focus highlights the broad impact of neurological disorders and the urgent need for innovative treatments. By targeting both a chronic autoimmune disease and an acute substance-induced condition, Quantum BioPharma is leveraging its expertise to address diverse neurological challenges. The imaging collaboration with Massachusetts General Hospital for Lucid-MS underscores the scientific rigor behind the program, potentially accelerating its pathway to market.
For more information on Quantum BioPharma's latest news, visit the company’s newsroom at https://ibn.fm/QNTM. This press release is disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
